Compass Pathways logo

Compass Pathways

NASDAQ: CMPS

UK-based Compass Pathways are one of the most prolific players in the emergent psilocybin space, actively conducting clinical trials to demonstrate the safety of psilocybin, and its potential to tackle treatment-resistant depression.

Compass IPO’d on Friday 18th September, 2020, on the Nasdaq.

The US Food and Drug Administration (FDA) awarded a “Breakthrough Therapy” designation to Compass for their research into the use of psilocybin for severe depression. This allows the Company to accelerate the (usually very slow) development and review of their drugs. Typically, such a designation is only approved where early evidence suggests the drug in question could pose a significant improvement versus currently-available therapy.

Compass has conducted, and is conducting, a range of registered clinical trials across the world. In the United Kingdom, the Company has worked with the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King’s College London to successfully conduct a double-blind, placebo-controlled study with nearly ninety participants between 18-65 years of age. The study found that psilocybin was well-tolerated by the healthy adult volunteers.

Compass Pathways has some well-known investors, including Peter Thiel (PayPal co-founder).

Compass Pathways (USD)
$40.83
9.46%
$3.53

Compass’ Patents

Compass has a number of patents pending in the US pertaining to psilocybin.

The Company has an investigational psilocybin formulation dubbed COMP360, which it developed and produces. This is used in Compass’ clinical trials, including a Phase 2 trial evaluating the safety and efficacy of psilocybin in cancer patients with major depressive disorder.

Patents

US10519175B2  |  Granted  Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Priority Date: 2017-10-09  |  Status: Granted 2019-12-31 (expires 2038-10-09)

General Subject Matter: Treating drug resistant depression with crystalline psilocybin in the form Polymorph A

US20200331939  |  Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Priority Date: 2017-10-09  |  Status: Pending in US

General Subject Matter: Oral dosage forms of crystalline psilocybin in the form Polymorph A

US20200199161A1 Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use

Priority Date: 2017-10-09  |  Status: Pending in US

General Subject Matter: Methods for manufacturing psilocybin from psilocin at greater than 100g scale

Join our Newsletter

Get the latest Company updates delivered to straight to your inbox.